Adenovirus-mediated expression of pig α(1, 3) galactosyltransferase reconstructs Gal α(1, 3) Gal epitope on the surface of human tumor cells

Cell Research

Volumn 11, Issue 2, 2001, Pages 116-124

  Xing, Li ^a   Xia, Guo Hong ^a   Fei, Jian ^a   Huang, Fang ^a   Guo, Li He ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Adenoviral vector; Gal (1, 3) Gal; Galactosyltransferase; Gene expression; Human tumor cell

Indexed keywords

DISACCHARIDE; EPITOPE; GALACTOSYL (1 3)GALACTOSE; GALACTOSYL-(1-3)GALACTOSE; GALACTOSYLTRANSFERASE; MEMBRANE PROTEIN; PLASMA PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; CYTOLOGY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; SWINE; TIME;

ADENOVIRIDAE; ANIMALS; BLOOD PROTEINS; CELL DIVISION; DISACCHARIDES; EPITOPES; GALACTOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; SWINE; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0035376204     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290076     Document Type: Article

References (25)

1. Blanken WM, Van den Eijnden DH. Biosynthesis of terminal Gal α(1-3) Gal β(1-4) GlcNAc-R oligosaccharide sequences on glycoconjugates: Purification and acceptor specificity of a UDP-Gal:N-acetyllactosaminide αl-3-galactosyltransferase from calf thymus. J Biol Chem 1985; 260:12927-34.
2. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263:17755-62.
3. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:β-D-Gal(1, 4)-D-GlcNAcα(1, 3)-galactosyltransferase cDNA. J Biol Chem 1990; 265:7055-61.
4. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-a-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56:1730-7.
5. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993; 82:2485-93.
6. Cooper DKC. Xenoantigens and xenoantibodies. Xeno-transplantation. 1998; 5:6-17.
7. Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, et al. Sensitization of cells and retroviruses to human serum by α(1-3)galactosyltransferase. Nature 1996; 379:85-8.
8. Schweighoffer T, Schmidt W, Buschle M, Birnstiel ML. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines. Gene Ther 1996; 3:819-24.
9. Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997; 18:281-5.
10. LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α(1,3) galactosyltransferase. Cancer Res 1999; 59:3417-23.
11. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of a-galactosyl epitopes by recombinant α(1, 3) galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996; 56:3069-74.
12. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1999; 6:113-38.
13. Xing L, Xia GH, Bai XF, Fei J, Guo LH. Adenovirus-mediated expression of RNA transcripts complementary to the pig α (1, 3) galactosyltransferase mRNAs inhibits the expression of Galα(1, 3) Galepitope. Acta Pharmacol Sin 2000; 21:1005-10.
14. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology. 1988; 163:614-7.
15. Xing L, Xia GH, Fei J, Bai XF, Guo LH. Adenovirus-mediated expression of human secretor type α(1, 2) fucosyltransferase leads to reduction in the level of Gal α(1, 3) Gal epitope. Acta Pharmacol Sin 2000; 21:807-13.
16. Hitt M, Bett AJ, Addison CL, Prevec L, Graham FL. Techniques for human adenovirus vector construction and characterization, in: Methods in molecular genetics. Academic Press; 1995; 7:13-45.
17. Osman N, McKenzie IF, Ostenried K, Ioannou YA, Desnick RJ, Sandrin MS. Combined transgenic expression of a-galactosidase and α(1, 2)-fucosyltransferase leads to optimal reduction in the major xenoepitope Gal α(1, 3) Gal. Proc Natl Acad Sci USA 1997; 94:14677-82.
18. Larsen RD, Ernst LK, Nair RP, Lowe JB. Molecular cloning, sequence, and expression of a human GDP-L-fucose:β-D-galactoside 2-α-L-fucosyltransferase cDNA that can form the H bood group antigen. Proc Natl Acad USA 1990; 87:6674-8.
19. Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: α(1, 3) galactosyltransferase gene therapy. Anticancer Res 1998; 18:2301-8.
20. Mollnes TE, Fiane AE. Xenotransplantation: how to overcome the complement obstacle? Mol Immunol 1999; 36:269-76.
21. Roth J. Subcellular organization of glycosylation in mammalian cells. Biochim Biophys Acta 1987; 906:405-36.
22. Gorelik E, Duty L, Anaraki F, Galili U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α(1, 3) galactosyltransferase gene transfection. Cancer Res 1995; 55:4168-73.
23. Cohney S, McKenzie IF, Patton K, Prenzoska J, Ostenreid K, Fodor WL, et al. Down-regulation of Galα(1, 3) Gal expression by α(1, 2) fucosyltransferase: Further characterization of α(1, 2) fucosyltransferase transgenic mice. Transplantation 1997; 64:495-500.
24. Sharma A, Okabe J, Birch P, McClellan SB, Martin MJ, Platt JL, et al. Reduction in the level of Gal α(1, S)Gal in transgenic mice and pigs by the expression of an α(1, 2) fucosyltransferase. Proc Natl Acad Sci USA 1996; 93:7190-5.
25. Xing L and Guo LH. FUT2 gene involved in expression of H blood group antigen on surface of human tumor cell lines BEL-7404, SGC-7901, and SPC-A-1. Acta Pharmacol Sin 2000; 21:997-1001.